1. Pink Sheet

Agile’s Twirla Heads To Advisory Committee: No Mystery Why

 
• By Michael McCaughan

Contraceptive patch has had rocky regulatory path with US FDA. To Agile’s credit, the company pulls no punches in its shareholder filings in explaining the situation.

Trade union advisory committee meeting . Audience at the conference hall. Black and white shot. - Image

In an era where most new products moving through the US Food & Drug Administration don’t go before a public advisory committee, there can often be some mystery that ensues when a new meeting topic is announced: why is FDA taking this application to committee?

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers